132.75 USD
-1.73 (-1.29%)
133 USD
+0.25 (+0.19%)
ILMN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. ILMN scores excellent on profitability, but there are some minor concerns on its financial health. ILMN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ILMN was profitable.
ILMN had a positive operating cash flow in the past year.
In multiple years ILMN reported negative net income over the last 5 years.
Each year in the past 5 years ILMN had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 11.38%, ILMN belongs to the top of the industry, outperforming 91.23% of the companies in the same industry.
ILMN has a better Return On Equity (29.53%) than 96.49% of its industry peers.
ILMN's Return On Invested Capital of 16.40% is amongst the best of the industry. ILMN outperforms 91.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROIC | 16.4% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ILMN has a better Profit Margin (16.39%) than 89.47% of its industry peers.
With an excellent Operating Margin value of 20.41%, ILMN belongs to the best of the industry, outperforming 85.96% of the companies in the same industry.
ILMN's Operating Margin has declined in the last couple of years.
ILMN's Gross Margin of 66.74% is amongst the best of the industry. ILMN outperforms 87.72% of its industry peers.
ILMN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% |
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ILMN is still creating some value.
ILMN has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for ILMN has been increased compared to 5 years ago.
ILMN has a worse debt/assets ratio than last year.
2.2 Solvency
ILMN has an Altman-Z score of 4.41. This indicates that ILMN is financially healthy and has little risk of bankruptcy at the moment.
ILMN has a Altman-Z score of 4.41. This is in the better half of the industry: ILMN outperforms 78.95% of its industry peers.
The Debt to FCF ratio of ILMN is 1.99, which is an excellent value as it means it would take ILMN, only 1.99 years of fcf income to pay off all of its debts.
ILMN's Debt to FCF ratio of 1.99 is amongst the best of the industry. ILMN outperforms 87.72% of its industry peers.
ILMN has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
ILMN has a Debt to Equity ratio (0.42) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Altman-Z | 4.41 |
ROIC/WACC1.54
WACC10.65%
2.3 Liquidity
A Current Ratio of 1.43 indicates that ILMN should not have too much problems paying its short term obligations.
The Current ratio of ILMN (1.43) is worse than 78.95% of its industry peers.
ILMN has a Quick Ratio of 1.12. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
ILMN has a Quick ratio of 1.12. This is in the lower half of the industry: ILMN underperforms 70.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
ILMN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 152.02%, which is quite impressive.
ILMN shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -17.93% yearly.
The Revenue has decreased by -2.32% in the past year.
The Revenue has been growing slightly by 4.29% on average over the past years.
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
3.2 Future
Based on estimates for the next years, ILMN will show a very strong growth in Earnings Per Share. The EPS will grow by 24.49% on average per year.
The Revenue is expected to grow by 3.93% on average over the next years.
EPS Next Y96.03%
EPS Next 2Y44.64%
EPS Next 3Y34.05%
EPS Next 5Y24.49%
Revenue Next Year-0.86%
Revenue Next 2Y0.68%
Revenue Next 3Y2.56%
Revenue Next 5Y3.93%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 30.45, ILMN can be considered very expensive at the moment.
68.42% of the companies in the same industry are more expensive than ILMN, based on the Price/Earnings ratio.
ILMN's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.84.
With a Price/Forward Earnings ratio of 25.90, ILMN can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, ILMN is valued a bit cheaper than 77.19% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.40, ILMN is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.45 | ||
| Fwd PE | 25.9 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ILMN indicates a rather cheap valuation: ILMN is cheaper than 80.70% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ILMN is valued cheaper than 87.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.28 | ||
| EV/EBITDA | 18.29 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ILMN has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ILMN's earnings are expected to grow with 34.05% in the coming years.
PEG (NY)0.32
PEG (5Y)N/A
EPS Next 2Y44.64%
EPS Next 3Y34.05%
5. Dividend
5.1 Amount
ILMN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
132.75
-1.73 (-1.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.82%
Inst Owner Change1.59%
Ins Owners0.18%
Ins Owner Change-0.42%
Market Cap20.28B
Revenue(TTM)4.29B
Net Income(TTM)703.00M
Analysts72.86
Price Target126.28 (-4.87%)
Short Float %4.86%
Short Ratio4.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.9%
Min EPS beat(2)12.52%
Max EPS beat(2)15.27%
EPS beat(4)3
Avg EPS beat(4)5.34%
Min EPS beat(4)-7.76%
Max EPS beat(4)15.27%
EPS beat(8)6
Avg EPS beat(8)97.15%
EPS beat(12)10
Avg EPS beat(12)231.96%
EPS beat(16)13
Avg EPS beat(16)178.01%
Revenue beat(2)0
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.66%
Min Revenue beat(4)-1.21%
Max Revenue beat(4)-0.18%
Revenue beat(8)3
Avg Revenue beat(8)-0.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.57%
Revenue beat(16)5
Avg Revenue beat(16)-0.78%
PT rev (1m)4.82%
PT rev (3m)10.24%
EPS NQ rev (1m)0.02%
EPS NQ rev (3m)3.03%
EPS NY rev (1m)1.32%
EPS NY rev (3m)4.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.72%
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.45 | ||
| Fwd PE | 25.9 | ||
| P/S | 4.73 | ||
| P/FCF | 20.28 | ||
| P/OCF | 18.08 | ||
| P/B | 8.52 | ||
| P/tB | 19.45 | ||
| EV/EBITDA | 18.29 |
EPS(TTM)4.36
EY3.28%
EPS(NY)5.13
Fwd EY3.86%
FCF(TTM)6.54
FCFY4.93%
OCF(TTM)7.34
OCFY5.53%
SpS28.06
BVpS15.58
TBVpS6.83
PEG (NY)0.32
PEG (5Y)N/A
Graham Number39.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROCE | 20.76% | ||
| ROIC | 16.4% | ||
| ROICexc | 23.54% | ||
| ROICexgc | 43.23% | ||
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% | ||
| FCFM | 23.32% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Debt/EBITDA | 0.86 | ||
| Cap/Depr | 44.36% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 97.57% | ||
| Profit Quality | 142.25% | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 4.41 |
F-Score7
WACC10.65%
ROIC/WACC1.54
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
EPS Next Y96.03%
EPS Next 2Y44.64%
EPS Next 3Y34.05%
EPS Next 5Y24.49%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
Revenue Next Year-0.86%
Revenue Next 2Y0.68%
Revenue Next 3Y2.56%
Revenue Next 5Y3.93%
EBIT growth 1Y154.36%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year36.79%
EBIT Next 3Y17.14%
EBIT Next 5Y16.22%
FCF growth 1Y495.24%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y179.8%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%
ILLUMINA INC / ILMN FAQ
Can you provide the ChartMill fundamental rating for ILLUMINA INC?
ChartMill assigns a fundamental rating of 5 / 10 to ILMN.
What is the valuation status for ILMN stock?
ChartMill assigns a valuation rating of 6 / 10 to ILLUMINA INC (ILMN). This can be considered as Fairly Valued.
How profitable is ILLUMINA INC (ILMN) stock?
ILLUMINA INC (ILMN) has a profitability rating of 7 / 10.
How financially healthy is ILLUMINA INC?
The financial health rating of ILLUMINA INC (ILMN) is 5 / 10.
Can you provide the expected EPS growth for ILMN stock?
The Earnings per Share (EPS) of ILLUMINA INC (ILMN) is expected to grow by 96.03% in the next year.